Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,985 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. Doi Y, et al. Among authors: kato y, kato h. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01897-20. doi: 10.1128/AAC.01897-20. Print 2020 Nov 17. Antimicrob Agents Chemother. 2020. PMID: 32958718 Free PMC article. Clinical Trial.
Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae.
Hayakawa K, Nakano R, Hase R, Shimatani M, Kato H, Hasumi J, Doi A, Sekiya N, Nei T, Okinaka K, Kasahara K, Kurai H, Nagashima M, Miyoshi-Akiyama T, Kakuta R, Yano H, Ohmagari N. Hayakawa K, et al. Among authors: kato h. J Antimicrob Chemother. 2020 Mar 1;75(3):697-708. doi: 10.1093/jac/dkz501. J Antimicrob Chemother. 2020. PMID: 31789374
Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect.
Ohno Y, Aoyagi K, Arakita K, Doi Y, Kondo M, Banno S, Kasahara K, Ogawa T, Kato H, Hase R, Kashizaki F, Nishi K, Kamio T, Mitamura K, Ikeda N, Nakagawa A, Fujisawa Y, Taniguchi A, Ikeda H, Hattori H, Murayama K, Toyama H. Ohno Y, et al. Among authors: kato h. Jpn J Radiol. 2022 Aug;40(8):800-813. doi: 10.1007/s11604-022-01270-5. Epub 2022 Apr 9. Jpn J Radiol. 2022. PMID: 35396667 Free PMC article. Clinical Trial.
Response to RMED-D-22-00,258.R1.
Ohno Y, Aoyagi K, Arakita K, Doi Y, Kondo M, Banno S, Kasahara K, Ogawa T, Kato H, Hase R, Kashizaki F, Nishi K, Kamio T, Mitamura K, Ikeda N, Nakagawa A, Fujisawa Y, Taniguchi A, Ikeda H, Hattori H, Murayama K, Toyama H. Ohno Y, et al. Among authors: kato h. Jpn J Radiol. 2022 Aug;40(8):860-861. doi: 10.1007/s11604-022-01308-8. Epub 2022 Jun 25. Jpn J Radiol. 2022. PMID: 35751793 Free PMC article. No abstract available.
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Hayakawa K, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, Shinohara K, Hashimoto T, Hase R, Matono T, Kato H, Mawatari M, Hara H, Hamada Y, Saito S, Ohmagari N, Doi Y. Hayakawa K, et al. Among authors: kato h. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0051023. doi: 10.1128/aac.00510-23. Epub 2023 Sep 13. Antimicrob Agents Chemother. 2023. PMID: 37702483 Free PMC article.
A Case of Coronavirus Disease 2019 Treated With Ciclesonide.
Nakajima K, Ogawa F, Sakai K, Uchiyama M, Oyama Y, Kato H, Takeuchi I. Nakajima K, et al. Among authors: kato h. Mayo Clin Proc. 2020 Jun;95(6):1296-1297. doi: 10.1016/j.mayocp.2020.04.007. Epub 2020 Apr 15. Mayo Clin Proc. 2020. PMID: 32402512 Free PMC article. No abstract available.
Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship.
Kato H, Shimizu H, Shibue Y, Hosoda T, Iwabuchi K, Nagamine K, Saito H, Sawada R, Oishi T, Tsukiji J, Fujita H, Furuya R, Masuda M, Akasaka O, Ikeda Y, Sakamoto M, Sakai K, Uchiyama M, Watanabe H, Yamaguchi N, Higa R, Sasaki A, Tanaka K, Toyoda Y, Hamanaka S, Miyazawa N, Shimizu A, Fukase F, Iwai S, Komase Y, Kawasaki T, Nagata I, Nakayama Y, Takei T, Kimura K, Kunisaki R, Kudo M, Takeuchi I, Nakajima H. Kato H, et al. J Infect Chemother. 2020 Aug;26(8):865-869. doi: 10.1016/j.jiac.2020.05.005. Epub 2020 May 13. J Infect Chemother. 2020. PMID: 32405245 Free PMC article.
8,985 results